Tango Therapeutics, Inc.

NasdaqGM:TNGX Lagerbericht

Marktkapitalisierung: US$438.3m

Tango Therapeutics Management

Management Kriterienprüfungen 2/4

Tango Therapeutics CEO ist Barbara Weber , ernannt in Mar 2017, hat eine Amtszeit von 7.67 Jahren. Die jährliche Gesamtvergütung beträgt $3.39M , bestehend aus 18.5% Gehalt und 81.5% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 1.3% der Aktien des Unternehmens, im Wert von $5.70M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 1.1 Jahre bzw. 3.8 Jahre.

Wichtige Informationen

Barbara Weber

Geschäftsführender

US$3.4m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts18.5%
Amtszeit als Geschäftsführer7.7yrs
Eigentum des Geschäftsführers1.3%
Durchschnittliche Amtszeit des Managements1.1yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder3.8yrs

Jüngste Management Updates

Shareholders May Not Be So Generous With Tango Therapeutics, Inc.'s (NASDAQ:TNGX) CEO Compensation And Here's Why

May 30
Shareholders May Not Be So Generous With Tango Therapeutics, Inc.'s (NASDAQ:TNGX) CEO Compensation And Here's Why

Recent updates

Tango Therapeutics, Inc.'s (NASDAQ:TNGX) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Oct 31
Tango Therapeutics, Inc.'s (NASDAQ:TNGX) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Tango Therapeutics: Amgen Missteps Devalue PRMT5 Candidates Ahead Of Critical Data

Sep 10

What Tango Therapeutics, Inc.'s (NASDAQ:TNGX) 29% Share Price Gain Is Not Telling You

Sep 01
What Tango Therapeutics, Inc.'s (NASDAQ:TNGX) 29% Share Price Gain Is Not Telling You

Subdued Growth No Barrier To Tango Therapeutics, Inc. (NASDAQ:TNGX) With Shares Advancing 27%

Jun 29
Subdued Growth No Barrier To Tango Therapeutics, Inc. (NASDAQ:TNGX) With Shares Advancing 27%

Shareholders May Not Be So Generous With Tango Therapeutics, Inc.'s (NASDAQ:TNGX) CEO Compensation And Here's Why

May 30
Shareholders May Not Be So Generous With Tango Therapeutics, Inc.'s (NASDAQ:TNGX) CEO Compensation And Here's Why

Risks Still Elevated At These Prices As Tango Therapeutics, Inc. (NASDAQ:TNGX) Shares Dive 30%

Mar 19
Risks Still Elevated At These Prices As Tango Therapeutics, Inc. (NASDAQ:TNGX) Shares Dive 30%

Tango Therapeutics (NASDAQ:TNGX) Is In A Good Position To Deliver On Growth Plans

Mar 06
Tango Therapeutics (NASDAQ:TNGX) Is In A Good Position To Deliver On Growth Plans

Tango Therapeutics, Inc.'s (NASDAQ:TNGX) Share Price Could Signal Some Risk

Jan 08
Tango Therapeutics, Inc.'s (NASDAQ:TNGX) Share Price Could Signal Some Risk

Industry Analysts Just Upgraded Their Tango Therapeutics, Inc. (NASDAQ:TNGX) Revenue Forecasts By 15%

Nov 09
Industry Analysts Just Upgraded Their Tango Therapeutics, Inc. (NASDAQ:TNGX) Revenue Forecasts By 15%

New Forecasts: Here's What Analysts Think The Future Holds For Tango Therapeutics, Inc. (NASDAQ:TNGX)

Aug 12
New Forecasts: Here's What Analysts Think The Future Holds For Tango Therapeutics, Inc. (NASDAQ:TNGX)

Will Tango Therapeutics (NASDAQ:TNGX) Spend Its Cash Wisely?

May 10
Will Tango Therapeutics (NASDAQ:TNGX) Spend Its Cash Wisely?

Tango Therapeutics started at buy at Wainwright on synthetically lethal targets for cancer

Oct 20

Companies Like Tango Therapeutics (NASDAQ:TNGX) Are In A Position To Invest In Growth

Oct 05
Companies Like Tango Therapeutics (NASDAQ:TNGX) Are In A Position To Invest In Growth

Tango Therapeutics, Inc. (NASDAQ:TNGX) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Aug 13
Tango Therapeutics, Inc. (NASDAQ:TNGX) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Tango Therapeutics GAAP EPS of -$0.28 beats by $0.03, revenue of $5.78M beats by $0.12M

Aug 10

We're Not Worried About Tango Therapeutics' (NASDAQ:TNGX) Cash Burn

May 28
We're Not Worried About Tango Therapeutics' (NASDAQ:TNGX) Cash Burn

We're Interested To See How Tango Therapeutics (NASDAQ:TNGX) Uses Its Cash Hoard To Grow

Jan 06
We're Interested To See How Tango Therapeutics (NASDAQ:TNGX) Uses Its Cash Hoard To Grow

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Barbara Weber im Vergleich zu den Einnahmen von Tango Therapeutics verändert?
DatumGesamtvergütungGehaltUnternehmensgewinne
Sep 30 2024n/an/a

-US$123m

Jun 30 2024n/an/a

-US$116m

Mar 31 2024n/an/a

-US$112m

Dec 31 2023US$3mUS$626k

-US$102m

Sep 30 2023n/an/a

-US$100m

Jun 30 2023n/an/a

-US$107m

Mar 31 2023n/an/a

-US$111m

Dec 31 2022US$5mUS$575k

-US$108m

Sep 30 2022n/an/a

-US$101m

Jun 30 2022n/an/a

-US$92m

Mar 31 2022n/an/a

-US$71m

Dec 31 2021US$12mUS$514k

-US$58m

Sep 30 2021n/an/a

-US$45m

Jun 30 2021n/an/a

-US$52m

Mar 31 2021n/an/a

-US$56m

Dec 31 2020US$958kUS$492k

-US$52m

Vergütung im Vergleich zum Markt: BarbaraDie Gesamtvergütung ($USD3.39M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD2.24M).

Entschädigung vs. Einkommen: BarbaraDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

Barbara Weber (67 yo)

7.7yrs

Amtszeit

US$3,391,058

Vergütung

Dr. Barbara L. Weber, M.D., has been the President, Director and Chief Executive Officer of Tango Therapeutics Inc., since March 2017 and also served as Chairperson. Dr. Weber serves as a Director of OPY A...

Führungsteam

NamePositionAmtszeitVergütungEigentümerschaft
Barbara Weber
President7.7yrsUS$3.39m1.3%
$ 5.7m
Adam Crystal
President of Research & Development1.8yrsUS$3.11m0.025%
$ 110.5k
Alan Ashworth
Founder & Member of Scientific Advisory Boardno datakeine Datenkeine Daten
Levi Garraway
Founderno datakeine Datenkeine Daten
William Kaelin
Founder & Member of Scientific Advisory Boardno datakeine Datenkeine Daten
Timothy Lu
Founderno datakeine Datenkeine Daten
Antoni Ribas
Founder & Member of Scientific Advisory Boardno datakeine Datenkeine Daten
Timothy Redfern
Chief Financial Officerless than a yearkeine Datenkeine Daten
Michael Palmieri
Head of Technical Operationsless than a yearkeine Datenkeine Daten
Jannik Andersen
Chief Scientific Officer1.1yrskeine Datenkeine Daten
Douglas Barry
Chief Legal Officer3.3yrskeine Daten0.041%
$ 179.4k
Julie Carretero
Chief Human Resources Officerless than a yearkeine Datenkeine Daten

1.1yrs

Durchschnittliche Betriebszugehörigkeit

54.5yo

Durchschnittliches Alter

Erfahrenes Management: TNGXDas Führungsteam des Unternehmens gilt nicht als erfahren ( 1.1 Jahre durchschnittliche Betriebszugehörigkeit), was auf ein neues Team schließen lässt.

Vorstandsmitglieder

NamePositionAmtszeitVergütungEigentümerschaft
Barbara Weber
President7.7yrsUS$3.39m1.3%
$ 5.7m
Alan Ashworth
Founder & Member of Scientific Advisory Board3.8yrskeine Datenkeine Daten
William Kaelin
Founder & Member of Scientific Advisory Board3.8yrskeine Datenkeine Daten
Antoni Ribas
Founder & Member of Scientific Advisory Board3.8yrskeine Datenkeine Daten
Alexis Borisy
Independent Chairman7.8yrsUS$171.53k0.0046%
$ 20.4k
Mace Rothenberg
Independent Director3.7yrsUS$141.53k0.0046%
$ 20.4k
Kanishka Pothula
Independent Directorless than a yearkeine Datenkeine Daten
Lesley Calhoun
Independent Director3.7yrsUS$148.03kkeine Daten
Malte Peters
Independent Director6.2yrsUS$139.03k0.0046%
$ 20.4k
John Ketchum
Independent Director1.3yrsUS$375.87k0%
$ 0
Ulrich Elling
Member of Scientific Advisory Board3.8yrskeine Datenkeine Daten
John Doench
Member of Scientific Advisory Board3.8yrskeine Datenkeine Daten

3.8yrs

Durchschnittliche Betriebszugehörigkeit

62.5yo

Durchschnittliches Alter

Erfahrener Vorstand: TNGXDie Vorstandsmitglieder gelten als erfahren (3.8 Jahre durchschnittliche Amtszeit).